At the end of 2019, a new team, Leadingtac Bio, emerged on the track of targeted protein degradation in Zhangjiang Pharmaceutical Valley, Pudong, Shanghai. This company focuses on the research and development of new small- molecule drugs in autoimmune and oncology diseases. Although it was infant, its founder, Yan Feng, was already one of the pioneers of innovative drug development in China in 2005.